Related Experiment Video
Updated: Nov 7, 2025

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
Published on: December 17, 2021
Implications of COVID-19 infection on patients with uveitis under biologic treatment
Abdulrahman F AlBloushi1, Abdullah M Alfawaz1, Ahmed M Abu El Asrar2,3
1Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Background/Aims:
To investigate the incidence, severity of COVID-19 infection and the outcomes in patients with uveitis treated with biologic agents during COVID-19 pandemic.
Methods:
In this prospective study, we included all patients with uveitis treated with biologic agents and tested for COVID-19 infection between May 2020 and October 2020.
Results:
A total of 59 patients were identified. Behçet's disease was the most common diagnosis (64.4%). Infliximab was the most frequent biologic agent used (61%). Nine (15.3%) patients were tested positive for COVID-19. None of the patients with positive COVID-19 test developed any COVID-19-related symptoms during follow-up. Of the nine patients with positive COVID-19 test, only two patients had uveitis flare-up after the biologic suspension.
Conclusion:
Uveitis patients under biologic therapy can be silent carriers for COVID-19.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Myocarditis III: Medical Management
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Glaucoma: Overview
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

